Methotrexate-based Chemo-immunotherapy Followed by Maintenance Therapy for Patients > 65 Years With Central Nervous System (CNS)-Lymphoma — PRIMAIN  

Primary Non Hodgkin Lymphoma of the Central Nervous System Clinical Trial

Official title: Treatment of Patients Over 65 Years With Primary CNS Lymphoma: High-dose Methotrexate Combined With Chemo-immunotherapy Followed by Maintenance Therapy

Status Recruiting

Clinical Trial Summary

The purpose of this study is to determine whether combined chemotherapy [rituximab plus high dosage methotrexate, lomustine, and procarbazine] followed by maintenance therapy with procarbazine is effective in the treatment of cerebral Non Hodgkin lymphoma [PCNSL] in patients > 65 years.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, Non-Hodgkin
• Primary Non Hodgkin Lymphoma of the Central Nervous System

• NCT number: NCT00989352
• Study type: Interventional
• Source: University Hospital Freiburg
• Contact: Gerald Illerhaus, PD Dr.
• Phone: +497612703785
• Email: Gerald.Illerhaus@uniklinik-freiburg.de
• Status: Recruiting
• Phase: Phase 2
• Start date: September 2009
• Completion date: September 2011